Author: Dr. Guillermo Moreno-Sanz, Global Scientific DirectorGuillermo is a scientific expert with a passion for cannabinoid pharmacology. He holds a PhD in Neurosciences from Complutense University in Madrid and developed his academic career at the University of California, Irvine, which he joined as a Fulbright scholar, authoring over 30 scientific publications as well as 3 patents describing the role of the endocannabinoid system in pain perception. Before joining Khiron, he acted as a consultant to the international medical cannabis industry, including its participation in the 2017 report "The health effects of cannabis and cannabinoids" by the National Academies of Sciences of the United States.

June 8, 2021


The approval of epidyolex for the treatment of refractory pediatric epilepsy is providing an increasing body of evidence on the therapeutic potential of cannabidiol (CBD), which had already showed promise […]

Read More
May 7, 2021

A tale of two (cannabis) registries

A tale of two (cannabis) registries In the last month, we have seen the almost simultaneous publication of the initial results from two different, formalized patient registries in the UK […]

Read More